Genfit S.A. (EPA: GNFT)

France flag France · Delayed Price · Currency is EUR
3.910
-0.010 (-0.26%)
Aug 30, 2024, 5:35 PM CET
18.48%
Market Cap 194.68M
Revenue (ttm) 34.48M
Net Income (ttm) -28.89M
Shares Out 49.79M
EPS (ttm) -0.58
PE Ratio n/a
Forward PE 39.73
Dividend n/a
Ex-Dividend Date n/a
Volume 130,680
Open 3.935
Previous Close 3.920
Day's Range 3.850 - 3.975
52-Week Range 2.840 - 5.790
Beta 1.09
Analysts n/a
Price Target n/a
Earnings Date Sep 19, 2024

About Genfit

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patien... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 159
Stock Exchange Euronext Paris
Ticker Symbol GNFT
Full Company Profile

News

There is no news available yet.